News
HEMOTAG CPAS in the News
Designers: Rob Brady, Matt Vergin, and Emanuel Guzman, ROBRADY design, Sarasota, Florida, USA designed the HEMOTAG CPAS Cardiopulmonary Analysis System for Boca Raton, Florida-based high technology company Aventusoft LLC.
About Good Design:
HISTORY 1950-2020 - SEVENTY YEARS
The GOOD DESIGN® exhibition program began as a sponsorship between The Merchandise Mart in Chicago and the Museum of Modern Art in New York City and continues today by The Chicago Athenaeum: Museum of Architecture and Design.
The program called for three shows a year: one during the Chicago winter furniture market in January, another coinciding with the June summer market, and a November show based on the previous two exhibitions. Each year, a different prestigious designer was selected to curate the installation. Charles and Ray designed the 5,300-square-foot space for the inaugural installation in 1950, followed by Finn Juhl, Paul Rudolph, and Alexander Girard.
Now in its 70th year, GOOD DESIGN® is the oldest and the most prestigious Awards Program organized worldwide.
Founded in Chicago in 1950 by the former MoMA curator Edgar Kaufmann, Jr., together with such pioneers in modern design as Charles and Ray Eames, Russel Wright, George Nelson, and Eero Saarinen, GOOD DESIGN® honors the yearly achievements of the best industrial and graphic designers and world manufacturers for their pursuit of extraordinary design excellence.
For over seven decades since its inception, The Chicago Athenaeum continues the organization of the program to create a revived awareness about contemporary design and to honor both products and industry leaders in design and manufacturing that have chartered new directions and pushed the envelope for competitive products in the world marketplace. Every year, designers and manufactures in about 50 nations are honored for their singular achievements in producing hallmarks of contemporary design. For 70 years, everything and anything produced in and for the environment from a paperclip to a Boeing 787 Dreamliner or NASA Space Ship have been honored.
HEMOTAG CPAS Presenting at Life Science Summit 2020
HEMOTAG CPAS was showcased by CEO Kaustubh Kale at the 2020 Life Science Summit.
Press Release
Aventusoft Awarded $3 Million to Develop New Application to Diagnose and Monitor Congestive Heart Failure
BOCA RATON, Fla. (April 28, 2020) – Aventusoft, inventor of the "HEMOTAG CPAS" cardiac diagnostic system, today announced it has been awarded additional $ 3 million funding from the National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI). This SBIR FastTrack grant allows HEMOTAG CPAS to develop a new application for hemodynamic-guided therapy to diagnose and monitor congestive heart failure (CHF) in patients.
Standard patient monitoring methods such as blood pressure, weight, thoracic impedance, stethoscope auscultation or ECG rhythm strips are insufficient to reduce patient readmission. In contrast, pulmonary artery pressure (PAP) is recognized as the key parameter for effective management of CHF and reducing hospitalization rates however, existing technology to measure PAP is expensive or requires invasive procedures.
HEMOTAG CPAS aims to offer an alternate, absolute measurement which can be carried out by non-cardiologist care givers within 2 minutes, is entirely non-invasive and securely engages the patient’s care circle with actionable, specific diagnostic reports. HEMOTAG CPAS’ core technology has already been evaluated through multiple clinical studies and this additional funding allows broadening of the indications for use, giving caregivers a single, modern, compact, wireless system with unprecedented diagnostic power.
“Accurate close monitoring of cardiac patients non-invasively and from their homes is a major advance in the care of this ever-increasing population of heart failure patients. Improved outcomes and reduced hospital admissions, will be greatly beneficial to this group of patients numbered in the millions in this country alone.” - Robert Chait, MD (Program Director Cardiology Fellowship, University of Miami, JFK Medical Center).
Using this funding, HEMOTAG will be studied further in Tier 1 hospitals in South Florida, where the company is located. These trials are planned to be conducted at the Cleveland Clinic and HCA-JFK Hospital, and encompass clinical and health economic outcome data from 420 patients. The trials will be led by investigators Jaime Hernandez-Montfort, MD (Advanced Heart Disease and Transplant Cardiologist, Cleveland Clinic Florida), Robert Cubeddu, MD (Acting Chairman of the Department of Cardiology, Heart and Vascular Institute, Cleveland Clinic Florida), Robert Chait, MD (Program Director Cardiology Fellowship University of Miami, JFK Medical Center), and Waqas Ghumman, MD (Advanced Heart Failure & Transplant Cardiology, JFK Medical Center).
Independent safety and oversight of the clinical trial will be conducted by a highly accomplished committee comprised of Professor Marc Pfeffer, MD, PhD (Dzau Professor of Medicine, Harvard Medical School, Brigham and Women’s Hospital), Professor Charles Hennekens, MD (Senior Academic Advisor to the Dean, College of Medicine, Florida Atlantic University), Steven Borzak, MD (Associate Program Director, Cardiology Fellowship, University of Miami Miller School of Medicine at JFK Campus), and Professor Katherine Freeman-Costin, Dr.P.H. (Biostatistics Core Leader, Charles E. Schmidt College of Medicine, Florida Atlantic University).
“The HEMOTAG CPAS team is proud to serve our community by giving our clinician and patient partners cutting-edge telemedicine capabilities, with a cost-effective, ultra-compact and powerful hemodynamic diagnostic system,” stated Kaustubh Kale, Founder & CEO of Aventusoft.
In 2018, Aventusoft was selected by the Research Park at FAU to receive funding to participate in GrowFL’s strategic research economic gardening initiative in recognition of its potential to disrupt its industry and to significantly impact the regional economy.
Download the release here.
For further information contact info@hemotag.com.
